Lilly’s Phase 3b TOGETHER-PsA study demonstrates that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly outperforms Taltz monotherapy in treating adults with psoriatic arthritis (PsA) and obesity. The study, presented at the AAD Annual Meeting and published in Arthritis & Rheumatology, revealed that this dual therapy not only achieved the primary endpoint of ACR50 response but also met all key secondary endpoints, indicating robust efficacy. Notably, improvements in PsA disease activity were observable as early as Week 4, prior to any significant weight loss, suggesting that the combination therapy effectively addresses inflammation and disease severity independently of weight reduction.

The findings underscore the therapeutic potential of concurrently targeting PsA and obesity, conditions that often coexist and exacerbate each other. Participants receiving Taltz and Zepbound reported substantial enhancements in disease activity, fatigue, mental health-related quality of life, and cardiometabolic parameters, including significant reductions in BMI, blood pressure, and glucose levels. Approximately 65% of participants achieved Minimal Disease Activity (MDA), a critical milestone in PsA management, highlighting the treatment’s broad impact on both physical and mental health outcomes.

This study shifts the paradigm in PsA treatment by emphasizing the importance of integrated management strategies that address comorbidities like obesity. The results suggest a potential acceleration in drug development timelines for combination therapies targeting multifactorial diseases, paving the way for more comprehensive treatment approaches in clinical practice. As regulators review these findings, the implications for future clinical guidelines could redefine standard care for patients grappling with both PsA and obesity.

Source: investor.lilly.com